BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 10468699)

  • 1. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
    Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.
    Gragnani L; Fognani E; Piluso A; Boldrini B; Urraro T; Fabbrizzi A; Stasi C; Ranieri J; Monti M; Arena U; Iannacone C; Laffi G; Zignego AL;
    Hepatology; 2015 Apr; 61(4):1145-53. PubMed ID: 25431357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
    Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
    Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
    J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.
    Cresta P; Musset L; Cacoub P; Frangeul L; Vitour D; Poynard T; Opolon P; Nguyen DT; Golliot F; Piette JC; Huraux JM; Lunel F
    Gut; 1999 Jul; 45(1):122-8. PubMed ID: 10369715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S; Miglioli M; Barbara L
    J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
    Gragnani L; Fabbrizzi A; Triboli E; Urraro T; Boldrini B; Fognani E; Piluso A; Caini P; Ranieri J; Monti M; Laffi G; Zignego AL
    Dig Liver Dis; 2014 Sep; 46(9):833-7. PubMed ID: 24953206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
    Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F
    Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.
    Mazzaro C; Zorat F; Comar C; Nascimben F; Bianchini D; Baracetti S; Donada C; Donadon V; Pozzato G
    J Rheumatol; 2003 Aug; 30(8):1775-81. PubMed ID: 12913934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
    Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia.
    Adinolfi LE; Utili R; Zampino R; Ragone E; Mormone G; Ruggiero G
    Eur J Gastroenterol Hepatol; 1997 Nov; 9(11):1067-72. PubMed ID: 9431896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
    Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.
    Zuckerman E; Keren D; Slobodin G; Rosner I; Rozenbaum M; Toubi E; Sabo E; Tsykounov I; Naschitz JE; Yeshurun D
    J Rheumatol; 2000 Sep; 27(9):2172-8. PubMed ID: 10990230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.